ETRA vs NGNE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ETRA · ELECTRA THERAPEUTICS INC$7.80 ▲ 6.12%
NGNE · Neurogene$25.31 ▼ 1.33%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ETRA -41.1%
- NGNE -21.1%
Head to head
| Metric | ETRA | NGNE |
|---|---|---|
| Price | $7.80 | $25.31 |
| Change today | ▲ 6.12% | ▼ 1.33% |
| Market cap | $476.58M | $506.49M |
| Return, 3 months | – | -30.8% |
| Return, year to date | – | +22.9% |
| Return, 1 year | – | -5.4% |
| P/E (TTM) | -5.0 | -5.0 |
| P/B | -2.2 | 2.3 |
| P/E percentile vs own 5y | 91st | 35th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -150.0% | -56.6% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | – | -45.3% |
| Analyst target vs. price | +318.8% | +216.8% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 36 | 45 |
| 30-day volatility | 74.3% | 89.7% |
| Max drawdown, 1 year | -47.5% | -52.2% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- NGNE is the largest of the group by market value.
- NGNE carries the lowest trailing P/E.
- ETRA has been the calmest stock over the last 30 days.